Abstract
1 presented results from the Nordic IFN trial. Their fi ndings support results from earlier studies, showing a clear eff ect of adjuvant high-dose interferon alfa-2b on relapse-free survival in patients with high-risk melanoma, but no or a small eff ect on overall survival. In past investigations, this discrepancy might be partly explained by in suffi cient follow-up time because many studies have been prematurely fi nalised before most of the expected deaths had occurred. 2,3 Therefore, an important merit of the Nordic IFN trial is its long length of follow-up; however, this time might still not be long enough. Stadler and colleagues' study 4
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
